[1] Lafranco Dafflon M,Tran V T,Guex-Crosier Y,et al.Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation:indications,efficacy and side effects[J].Graefes Arch Clin Exp Ophthalmol,1999,237(4):289-295.
[2] van der Reis M I,La Heij E C,De Jong-Hesse Y,et al.A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections[J].Retina,2011,31(8):1449-1469.
[3] 张庆华,金中秋,宋艳萍,等.脉络膜上腔不同给药途径治疗葡萄膜炎的实验研究[J].眼科新进展,2003,23(4):257-259.
[4] 刘家琦,李凤鸣.实用眼科学[M].3版. 北京:人民卫生出版社,2010:14-18.
[5] 金中秋,张庆华,宋艳萍,等.脉络膜上腔给药治疗兔眼穿通伤[J].国际眼科杂志,2003,3(2):18-20.
[6] Einmahl S,Savoldelli M,D'Hermies F,et al.Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye[J].Invest Ophthalmol Vis Sci,2002,43(5):1533-1539.
[7] Olsen T W,Feng X,Wabner K,et al.Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model[J].Invest Ophthalmol Vis Sci,2011,52(7):4749-4756.
[8] Olsen T W,Feng X,Wabner K,et al.Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment[J].Am J Ophthalmol,2006,142(5):777-787.
[9] Patel S R,Berezovsky D E,McCarey B E,et al.Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posteriorsegment of the eye[J].Invest Ophthalmol Vis Sci,2012,53(8):4433-4441.
[10] Patel S R,Lin A S,Edelhauser H F,et al.Suprachoroidal drug delivery to the back of the eye using hollow microneedles[J].Pharm Res,2011,28(1):166-176.
[11] Jiang J,Moore J S,Edelhauser H F,et al.Intrascleral drug delivery to the eye using hollow microneedles[J].Pharm Res,2009, 26(2):395-403.
[12] Li F,Hurley B,Liu Y,et al.Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration[J].Open Ophthalmol J,2012,6(1):54-58.
[13] 游向东,金中秋,吴建国,等.壳聚糖缓释给药系统植入脉络膜上腔治疗兔眼穿通伤[J].国际眼科杂志,2005,5(1):74-76.
[14] 张庆华.脉络膜上腔给药治疗眼病的实验研究[D].第一军医大学,2003.
[15] Bourges J L,Gautier S E,Delie F,et al.Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles[J].Invest Ophthalmol Vis Sci,2003,44(8):3562-3569.
[16] 陈建斌,胡庆军,解孝林,等.左旋氧氟沙星聚乳酸眼内缓释植片研制及其体外释药实验[J].中国医院药学杂志,2007,27(9):1194-1197.
[17] Fang J Y,Chen J P,Leu Y L,et al.Temperature-sensitive hydrogels composed of chitosan and hyaluronic acid as injectable carriers for drug delivery[J].Eur J Pharm Biopharm,2008,68(3):626-636.
[18] Romagnoli M,Belmontesi M.Hyaluronic acid-based fillers:theory and practice[J].Clin Dermatol,2008,26(2):123-159.
[19] Kim J K,Srinivasan P,Kim J H,et al.Structural and antioxidant properties of gamma irradiated hyaluronic acid[J].Food Chemistry,2008,109(4):763-770.
[20] Bajaj G,Kim M R,Mohammed S I,et al.Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors[J].J Control Release,2012,158(3):386-392.
[21] Taglienti A,Valentini M,Sequi P,et al.Characterization of methylprednisolone esters of hyaluronan in aqueous solution:conformation and aggregation behavior.Biomacromolecules,2005, 6(3):1648-1653.
[22] Muller R H,Keck C M.Challenges and solutions for the delivery of biotech drugs-a review of drugnanocrystal technology and lipid nanoparticles[J].J Biotechnol,2004,113(1-3):151-170.
[23] Shegokar R,Singh K K,Müller R H.Production & stability of stavudine solid lipid nanoparticles-from lab to industrial scale[J].Int J Pharm,2011,416(2):461-470.
[24] Chhablani J,Kim J S,Freeman W R,et al.Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy[J].Int J Ophthalmol,2013,6(1):62-66.
[25] 陈艺霞.静态定量视野检查在临床眼病诊断上的探讨[J].实用医技杂志,2005,12(5):612-613.
[26] 张静楷,颜华,吴梅筠,等.视觉诱发电位对挫伤眼视神经损伤的评价[J].眼外伤职业眼病杂志,2003,25(2):93-94. |
